3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Endocrine
2
CNS
2
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
von Hippel-Lindau Disease
2
Neoplasm Metastasis
2
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Neuroectodermal Tumors, Primitive
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Interventions
belzutifan
2
Everolimus
2
Blood Specimen Collection
2
tanespimycin
1
spartalizumab
1
palbociclib
1
lenvatinib
1
cabozantinib
1
Sunitinib
1
PT2385
1
Oxygen-15
1
Nivolumab
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
belzutifan
×
Genitourinary
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled